Discover a comprehensive list of brain banks worldwide, facilitating Alzheimer's and Parkinson's research on Alzforum.

Score another one for amyloid immunotherapy. The anti-pyroglutamated amyloid antibody donanemab has posted positive top-line results in the Phase 3 Trailblazer-Alz2 study, according to an Eli Lilly ...

Dozens of rodents have been generated that model various aspects of ALS, like motor impairment or degeneration of motor neurons. No model recapitulates the human disease perfectly. By organizing ...

The gene PSEN2 encodes presenilin-2, a subunit of γ-secretase, the aspartyl protease responsible for Aβ generation. Missense mutations in PSEN2 are a rare cause of early onset Alzheimer's disease ...

Mouse cell biology study suggests that a seizure drug rescues neuronal hyperexcitability resulting from loss of BIN1. Prior work tied this AD risk factor to excitatory neurons.

An interactive timeline of the evolution of Alzheimer's Disease research.

Big Data Insights: Blood Signatures of Cognitive Decline, Aging, APOE4 RESEARCH NEWS 2025-07-23 Research News In the “omics” era, where bigger is better, the Global Neurodegeneration Proteomics ...

In a watershed moment for the field, the U.S. Food and Drug Administration today approved the first Alzheimer’s treatment that tackles the underlying disease pathology. Biogen and Eisai’s anti-amyloid ...

Time to rewrite the brain anatomy textbook? In addition to the outermost dura, middle arachnoid, and innermost pia membranes surrounding the brain, researchers led by Kjeld Møllgård, University of ...

The first direct-to-consumer Alzheimer’s disease blood test has arrived. Quest Diagnostics, a worldwide diagnostic service headquartered in Secaucus, New Jersey, announced on July 31 that it would ...

After years of fits and starts, anti-amyloid immunotherapies are finally hitting their target effectively. At least four drugs have now demonstrated the ability to clear plaques from the brain: ...

Eisai and Biogen yesterday announced positive topline results from the Phase 3 Clarity trial of their anti-amyloid antibody lecanemab. The drug slowed decline on the primary endpoint, CDR-SB, by 27 ...